Protara Therapeutics, Inc. (identified in the filing as Proteon Therapeutics, Inc.) — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; balance sheet compared with December 31, 2015. The filing entity is Proteon Therapeutics, Inc.; the supplied company metadata names Protara Therapeutics, Inc.
Business context
Proteon was a late-stage biopharmaceutical company developing vonapanitase for vascular access in patients with chronic kidney disease. It had no approved products and had not generated product sales. PATENCY-1, its Phase 3 trial in radiocephalic arteriovenous fistulas (AVFs), completed enrollment in October 2015, with top-line data expected in December 2016. PATENCY-2 began enrolling in August 2015, with enrollment completion expected in Q1 2017.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Revenue | No product revenue; the statements report no revenue for the quarter | No product revenue |
| Research and development expense | $4.349 million | $2.633 million |
| General and administrative expense | $2.470 million | $1.987 million |
| Total operating expenses / operating loss | $6.819 million | $4.620 million |
| Other income | $0.267 million | $0.040 million |
| Net loss | $6.552 million | $4.580 million |
| Net loss per share, basic and diluted | $0.40 | $0.28 |
| Cash and cash equivalents | $24.062 million | $40.031 million at Dec. 31, 2015 |
| Available-for-sale investments | $35.326 million | $25.232 million at Dec. 31, 2015 |
| Total cash, equivalents and investments | $59.388 million | $65.263 million at Dec. 31, 2015 |
| Total assets | $61.342 million | $67.538 million at Dec. 31, 2015 |
| Total liabilities | $3.588 million | $4.133 million at Dec. 31, 2015 |
Net cash used in operating activities was $5.894 million, versus $3.873 million in Q1 2015. Investing activities used $10.115 million, principally reflecting purchases of available-for-sale investments net of maturities; financing activities provided $0.012 million from option exercises. Cash and cash equivalents declined by $15.969 million during the quarter. The company had no reported debt. Current assets were $60.441 million against current liabilities of $3.588 million. The filing gives no meaningful operating margin because it reported no product revenue.
Changes versus the prior comparable period
- Net loss increased by $1.972 million, to $6.552 million. Operating expenses rose $2.199 million; management attributed the increase chiefly to higher R&D spending.
- R&D expense increased $1.716 million. External vonapanitase costs rose $1.128 million, including $1.0 million for manufacturing pre-validation and validation and $0.1 million for clinical activity; internal R&D costs rose $0.588 million, primarily due to personnel costs.
- G&A expense increased $0.483 million, primarily due to personnel and overhead, partly offset by lower public-company costs.
- Other income included $0.184 million of realized and unrealized gains on foreign currency forwards. The company did not apply hedge accounting, so fair-value changes flowed through earnings.
Outlook, risks and unusual items
- Management estimated that available cash, cash equivalents and investments would fund operations and capital expenditures into Q4 2017, including PATENCY-1 results, PATENCY-2 enrollment and CMC activities. The filing cautions that actual spending may shorten this runway and states that existing resources were not expected to fund completion of PATENCY-2.
- The company expected increasing operating losses and anticipated needing additional capital. Its $40 million at-the-market equity program was effective, but no sales had begun as of March 31, 2016; future issuance could dilute shareholders.
- Lonza manufacturing purchase obligations totaled CHF 9.5 million: CHF 1.9 million due within one year and CHF 7.6 million due within one to three years. The filing also describes a $1.9 million order for a batch scheduled to begin in July 2016 and a CHF 7.6 million order for four batches scheduled to begin in June 2017. Operating lease minimum payments totaled $0.378 million.
- Key development risk: the Phase 2 primary efficacy endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. The favorable radiocephalic-AVF subgroup findings were not prespecified and may not be reproduced in Phase 3. FDA may require both Phase 3 trials or additional studies; the company only contemplated discussing a possible BLA based on PATENCY-1 if results were sufficiently compelling.
- Other material risks include clinical efficacy, safety and enrollment; regulatory approval; reliance on third-party manufacturers and CROs; single-source API supply; Swiss franc exposure; additional financing and dilution; reimbursement and eventual market acceptance. The company reported no litigation expected to have a material adverse effect and no off-balance-sheet arrangements.
- Disclosure controls were assessed as effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether PATENCY-1 results met the primary endpoint and how the findings compare with the non-prespecified Phase 2 subgroup analyses.
- PATENCY-2 enrollment progress, projected completion timing and the financing required to complete the trial.
- Actual cash burn and runway relative to management’s Q4 2017 estimate, including any ATM sales or other financing.
- Lonza manufacturing milestones, purchase commitments, foreign-exchange exposure and readiness of CMC activities for a potential filing.
- Any FDA feedback on whether one Phase 3 trial could support a BLA, and any additional studies or manufacturing requirements.